Goldman Sachs maintained a Buy rating on FMC despite slashing its price target from $43 to $19 in late 2025, citing generic competition in Latin America as a key threat. However, FMC's stock plummeted 60.9% over the following year, driven by worsening generic competition, large goodwill impairments, credit rating downgrades, and negative earnings. The company faced significant revenue declines and negative equity, with debt far exceeding market cap. Analysts have since lowered targets and ratings, reflecting the deep challenges FMC faces, and the stock remains near its lows with uncertain recovery prospects.
FMC trades at USD 6.18 on Pluang as of Oct 31, 2026 03:02 WIB, recovering from a 52-week low of USD 4.47. The stock shows strong buying interest with 98% buy orders and a 29.29% gain in one day. Despite challenges, FMC offers a 6.74% dividend yield and has a market cap of $738.84M.
FMC Corporation reported a $2.07 billion GAAP net loss in Q3 2026, heavily impacted by $639 million in negative revenue effects from new commercial actions including pricing and rebate model changes in North America. Revenue fell to $106 million, dow...
FMC Corporation updated its Q3 2026 financial outlook, forecasting revenue between $65 million and $125 million and an adjusted EBITDA loss of $510 million to $565 million, significantly below expectations. The company cited a $625 million to $675 mi...
